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RESUMEN
En general tetrazoles 5-sustituidos se prepararon a través 
de reacciones de azida de sodio con nitrilos en un disol-
vente aromático en presencia de una sal de amina. El pre-
sente trabajo describe el proceso para la preparación de la 
2-butil-3-[[2’-(1H-tetrazol-5-il) [1,1’-bifenil]-4-il] metil]-1,3-
diazaespiro [4.4] non-1-en-4-ona [Irbesartán] por reac-
ción de la correspondiente 2-butil-3-[(2’-cianobifenil)-4-il] 
metil-1,3-diazaespiro [4.4] non -1-eno con una azida de 
sodio y clorhidrato de dimetilamina.
Palabras clave: Tetrazole; azida de sodio, sales de dimeti-
lamina; bifenilo ciano; irbesartán.
SUMMARY
In general 5-substituted tetrazoles were prepared through 
the reactions of sodium azide with nitriles in an aromat-
ic solvent in the presence of an amine salt. The present 
work describes process for the preparation of the 2-butyl-
3-[[2’-(1H-tetrazol-5-yl) [1,1’-biphenyl]-4-yl]methyl]-1,3-
diazaspiro[4.4]non-1-en-4-one [Irbesartan] by reaction 
of the corresponding 2-butyl-3-[(2’-cyanobiphenyl)-4-yl]
methyl-1,3-diazaspiro[4.4]non-1-ene with an sodium azide 
and dimethylamine hydrochloride.
Key words: Tetrazole; sodium azide; dimethylamine salts; 
cyano biphenyl; Irbesartan.
RESUM
En general tetrazols 5-substituïts es van preparar mitjan-
çant reaccions d’azida de sodi amb nitrils en un dissolvent 
aromàtic en presència d’una sal d’amina. Aquest treball 
descriu el procés per a la preparació de la 2-butil-3-[[2’-
(1H-tetrazol-5-il) [1,1’-bifenil]-4-il] metil]-1,3-diazaespiro 
[4.4] non-1-en-4-ona [irbesartán] per reacció de la corres-
ponent 2-butil-3-[(2’-cianobifenil)-4-il] metil-1,3-diazaes-
piro [4.4] non-1-è-4-ona amb una azida de sodi i clorhidrat 
de dimetilamina.
Mots clau: Tetrazol; azida de sodi, sals de dimetilamina, 
cianobifenil, irbesartan.
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INTRODUCTION 
 
Tetrazole derivatives have attracted much attention as raw 
materials for medicine, agricultural chemicals, foaming 
agents, and in the automobile inflator industry.1-4 Several 
methods for the synthesis of tetrazoles have been repor-
ted, but these conventional methods for the synthesis of 
tetrazoles have several disadvantages. e.g. the synthe-
tic method that uses amine salts in dimethylformamide 
(DMF)5–7 is laborious and due to the formation of bypro-
ducts; this method is applicable only to the synthesis 
of tetrazoles starting from simple nitriles. The synthetic 
method using NH4Cl in DMF
8, 9 also has disadvantages, as 
the reaction is accompanied by the sublimation of highly 
dangerous explosive NH4N3. Method that uses acid for the 
synthesis of tetrazole,10 the reaction proceeds relatively 
slow at room temperature and is also dangerous due to the 
production of poisonous and explosive HN3. Aromatic sol-
vents and organostannane catalysts are often used for the 
preparation of tetrazole compounds having polyfunctional 
groups from the respective nitriles.11–12 Stannane com-
pounds used in these reactions are generally highly toxic 
and it is often difficult to completely separate the desired 
tetrazole from the stannane compounds.
A versatile method for synthesizing many kinds of tetrazo-
les through safe and simple manipulation is shown below
RCN + NaN3 + NH .HCl
Solvent
30-135°C
HCl
N
N
N
HN
R
Nitrile Tetrazole
Irbesartan13 belongs to the class of drug called angiotensin 
II receptor antagonist antihypertensives. It is used to treat 
high blood pressure (hypertension), and it is also used 
to treat kidney problems caused by type 2 (non insulin-
dependent) diabetes. The current pharmaceutical product 
containing this drug is being sold by Sanofi Synthelabo 
using the trade name AVAPRO, in the form of tablets. Irbe-
sartan is a non-peptide compound, chemically described 
as a 2-butyl-3-[[2’-(1H-tetrazol-5-yl) [1, 1’-biphenyl]-4-yl]
methyl]-1,3-diazaspiro[4.4]non-1-en-4-one. Its empirical 
formula is C25H28N6O and the structural formula:
N N
O
HN
N N
N
(1)
Various processes for preparation of N-substituted hete-
rocyclic derivatives and their salts was disclosed in U.S. 
Patent No. 5,270,317.14 These compounds are angiotensin 
II antagonist that is especially useful in the treatment of 
cardiovascular ailments such as hypertension and heart 
failure, as well as in preventing disorders of central ner-
vous system, glaucoma, diabetic retinopathy, and diabetic 
nephropathy. As per the process described in the U.S. pa-
tent 5,270,317 Irbesartan is prepared by reaction of 2-n-
butyl-1, 3-diazaspiro[4,4]non-1-en-4-one hydrochloride 
(3) with 4-bromomethyl-2’-cyanobiphenyl (2) in the pre-
sence of sodium hydroxide, followed by a column chroma-
tography separation to produce 1-[(2’-cyanobiphenyl-4-yl)
methyl]-2-n-butyl-4-spirocyclopentane-2-imidazo- lin-
5-one (4), which upon reaction with tributyltin azide and 
trityl chloride followed by deprotection with HCl  produce 
Irbesartan (1).
N N
O
HN
N N
N
CH3
(1)
   
Br
NC
(3)(1)                                        (2)
N
HN
O
H3C
(4)
. HCl
   
CN
N N
O
CH3
(2)(3)                                        (4)
Irbesartan obtained by the process described in the 
5,270,317 patent may not have satisfactory purity. Unac-
ceptable amounts of impurities may be formed along with 
Irbesartan. The yield of Irbesartan obtained is very poor 
and the process involves column chromatographic puri-
fications; which are generally undesirable for large-scale 
operations, thereby making the process commercially un-
feasible. 
A process for the preparation of Irbesartan is reported 
wherein 1-[(2’-cyanobiphenyl-4-yl) methyl]-2-n-butyl-
4-spirocyclopentane-2-imidazo-lin-5-one is treated with 
sodium azide in the presence of triethylamine hydrochlori-
de in an inert polar aprotic solvent such as 1-methylpyrro-
lidin-2-one at a temperature of 121-123˚C.14 The solvent 
used is costly and not easily recovered thereby making 
the process unsuitable for commercial scale production. 
Isolation of Irbesartan from the reaction mixture is tedious 
and requires several critical layer separations and layer 
filtrations. Moreover, unacceptable amounts of impurities 
are formed along with Irbesartan, thus resulting in a poor 
product yield. Deshpande et.al.15 describes a process for 
the preparation of Irbesartan wherein 1-[(2’-cyanobiphen-
yl-4-yl) methyl]-2-n-butyl-4-spirocyclopentane-2-imidazo-
lin-5-one is treated with sodium azide in the presence of 
triethylamine and acetic acid. In literature 16 also disclosed 
the process for the preparation of tetrazole protected Irbe-
sartan from aromatic nitrile derivative in the presence of a 
protecting group, trialkyltin azide and o-xylene. In all the-
se processes Irbesartan synthesized using an organotin 
compound, which is difficult to remove and remains in the 
product as an impurity which is undesirable for Irbesartan.
Several other synthetic routes have been described in the 
literature for the preparation of Irbesartan. Most of the 
routes comprise the reaction of a  4-bromomethyl-2’-cya-
nobiphenyl compound with 2-n-butyl-1,3-diazaspiro[4,4]
non-1-en-4-one hydrochloride.17-20 The last step in most of 
the processes corresponds to the formation of the tetrazo-
le ring from a cyano group employing an azide derivative. 
An improved method for synthesis of Irbesartan has been 
described by K.V.V. Prasad Rao.21  Koguro et.al.
22
 prepared 
variety of 5-substituted tetrazoles by reaction of nitriles 
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with sodium azide in an aromatic solvent in the presence 
of amine salt.
To resolve the problems associated with the processes 
described in the prior art, there remains need for an im-
proved and commercially viable process of preparing a 
substantially pure Irbesartan, which will be suitable for 
large-scale preparation. For this reason processes which 
can afford Irbesartan, which must be free from any amou-
nt of tin content and its analogues which can be an envi-
ronmental hazard when employed as a medicament, are 
highly desirable. Processes should include non-hazardous 
and environmental friendly reagents, reduces cost of ma-
nufacturing, greater simplicity, increase purity, and increa-
ses yield of the product.
RESULTS AND DISCUSSION
The present invention describes the process for prepara-
tion of the Irbesartan (1) from its penultimate intermediate 
(4) using dimethylamine hydrochloride and sodium azide. 
Said intermediate (4) is formed by the reaction between 
4-bromomethyl-2’-cyanobiphenyl (2) and 2-n-butyl-1,3-
diazaspiro[4,4]non-1-en-4-one hydrochloride (3).
 
Stage 1: Preparation of Intermediate for Irbesartan
Br
NC
(2)
N
HN
O
H3C
(3)
CN
N N
O
CH3
(4)
+. HCl
NaOH
DMF
Stage 2: Preparation of Irbesartan
CN
N N
O
CH3
N N
O
HN
N N
N
CH3
Dimethylamine HCl 
NaN3
 Xylene
(4) (1)
The above mentioned reaction is carried out in presence of 
suitable solvents and chemical reagents. The final product 
is substantially pure Irbesartan. 
Various process parameters were optimized and the opti-
mum parameters for synthesis of stage-1 (4) and stage-2 
(1) are as:
For Stage-1: 4-bromomethyl-2’-cyanobipheny (2) – 1.05 
Mole; 2-n-butyl-1,3-diazaspiro[4,4]non-1-en-4-one hydro-
chloride (3) – 1.0 Mole; DMF – 4.5 Volume;  NaOH – 2.3 
Mole; Temperature – 30-35oC 
For Stage-2: 1-[(2’-cyanobiphenyl-4-yl) methyl]-2-n-
butyl-4-spirocyclopentane-2-imidazo-lin-5-one (4) – 1 
Mole; Xylene / n-Butanol  - 3 Volume; NaN3 – 2.5 Mole; 
Dimethylamine HCl – 3.5 Mole; Temperature - 115-120oC 
The tentative mechanism for this reaction is shown below, 
in analogy with mechanism reported for tetrazole forma-
tion using triethyl amine22
RCN
NaN3
NH .HCl
(Me2)NH2+. N3-
N
NN
N
H
R
. Me2NH
NaCl
NaN3
N
NN
N
Na
R
EXPERIMENTAL SECTION
Solvents and reagents were obtained from commercial 
sources and used without purification. Melting points were 
determined on a Veggo VMP-2 melting point apparatus. 
All the melting points were taken in an open capillary and 
uncorrected. The IR spectra were recorded in solid state 
as KBr dispersion using a Perkin-Elmer FT-IR spectrom-
eter. The 1H NMR and 13C NMR spectra were recorded on 
Bruker 300-MHz spectrometer. The chemical shifts are re-
ported in δ parts per million (ppm) relative to TMS. The 
mass spectra were recorded on an API 2000 Perkin-Elmer 
PE-SCIEX mass spectrometer.
Preparation of 1-[(2’-cyanobiphenyl-4-yl) methyl]-2-n-
butyl-4-spirocyclopentane-2-imidazo-lin-5-one (4)
In a 3 L 3-necked flask, equipped with stirrer, thermome-
ter and reflux condenser, 2-n-butyl-1,3-diazaspiro[4,4]
non-1-en-4-one hydrochloride (3) (100 g) was mixed with 
Dimethylformamide (500 mL) at temperature 30˚C – 35˚C. 
40 g of NaOH is charged in single lot. Reaction mixture 
is stirred for 30 min. 4-bromomethyl-2’-cyanobiphenyl (2)
(112 g) was added in to the reaction mixture and stirred for 
12 h at the same temperature. To the mixture was added 
water (1120 mL) and toluene (560 mL) and stirred for 30 
min. Layers were separated and toluene layer after water 
wash subject to distillation. After complete removal of sol-
vent petroleum ether (50 mL) is added to residue and again 
distilled completely. Petroleum ether (342 mL) is added to 
residue and stirred for 1 h. Reaction mass was chilled at 
0˚C - 5˚C and maintained for 2 h, filtered and washed. Wet-
cake was dried at 50˚C – 55˚C for 10 – 12 h.
Dry weight of product: 150 g
Purification of Irbesartan intermediate (4) 23
In a 3 L 3-necked flask, equipped with stirrer, thermometer 
and reflux condenser, -[(2’-cyanobiphenyl-4-yl) methyl]-
2-n-butyl-4-spirocyclopentane-2-imidazo-lin-5-one (4) 
(100 g) was charged with Isopropyl alcohol (150 mL) and 
DM water (225 mL) at 30°-32°C. Resultant mixture was 
stirred for 90 minutes. Cool to 0-5°C and stir for 30-45 
minutes. Filter the solid and was wash it with chilled iso-
propyl alcohol (38 mL) and DM water (56 mL). Suck dry for 
15 minutes and dry the product under vacuum (about 10 
mmHg) at 45-50°C. 
Dry weight of product: 90 g
IR (KBr, cm-1): 2220.72 (CN stretching), 1720.08 (C=O 
amide stretching), 1628.73 (C=N stretching); Mass: MS(EI) 
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calculated for C25H28N3O (M
+ + 1) : 386.22, observed value : 
386.22 ; 1H-NMR (CDCl3) δ 7.77 (d, J=7.6 Hz, 1H), 7.65 (td, 
J=1.1, J=7.7 Hz,1H), 7.54 (J=4.1 Hz, 2H), 7.49 (d, J=7.6Hz, 
1H), 7.45 (d, J=7.7 Hz, 1H), 7.28 (d, J=8.10Hz,2H), 4.75 (s, 
2H), 2.35 (t, J=7.8 Hz, 2H), 2.06-1.93 (m, 6H), 1.88-1.84 
(m, 2H), 1.60 (quintet, J=7.4 Hz,2H), 1.34 (sextet, J=7.4 
Hz, 2H), 0.88 (t, J=7.3 Hz, 3H); 13C-NMR (CDCl3) 186.8, 
161.5, 144.7, 137.7, 137.2, 133.8, 132.9, 132.0, 129.4, 
127.7, 127.1, 118.6, 111.2, 76.6, 43.3, 37.5, 28.8, 27.8, 
26.1, 22.3, 13.7.
Preparation of Irbesartan (1)
In a 3 L 3-necked flask, equipped with stirrer, thermome-
ter and reflux condenser, charged n-Butanol (300 mL) and 
1-[(2’-cyanobiphenyl-4-yl) methyl]-2-n-butyl-4-spirocyclo-
pentane-2-imidazo-lin-5-one (4) (100 g). To the reaction 
mixture is added Dimethyl amine hydrochloride (74 g) and 
Sodium azide (42.5 g). Mixture was stirred for 30 minutes 
at a temperature of 30˚C. Slowly temperature was raised 
to 115-120oC and maintained for 24 h. The reactant mass 
was cooled to 30-32°C and water (250 mL), 30% Sodium 
hydroxide and Sodium nitrite were added and stirred for 
30 minutes. Aqueous layer was separated and washed 
with n-Butanol (50 ml). 25 mL Ethyl Acetate added to 
aqueous layer and adjusted pH 3.0 – 4.0 using 6N hydro-
chloric acid. Reaction mass filtered and wet-cake washed 
with water (300 mL). To wet cake was added 1500 mL Iso-
propyl alcohol and refluxed till clear reaction mass. After 
charcoalization filtrate was distilled to half volume under 
reduced pressure. Resultant mass was chilled at 0 - 5˚C, 
Maintain for 2 h at same temperature and Filtered. Wet 
cake dried under vacuum of about 10 mmHg. 
HPLC purity –  99.0%; Dry weight of product: 70 g 
Preparation of Irbesartan (1)
In a 3 L 3-necked flask, equipped with stirrer, thermome-
ter and reflux condenser, charged Xylene (300 mL) and 
1-[(2’-cyanobiphenyl-4-yl) methyl]-2-n-butyl-4-spirocyclo-
pentane-2-imidazo-lin-5-one (4) (100 g). To the reaction 
mixture is added Dimethyl amine hydrochloride (74 g) and 
Sodium azide (42.5 g). Mixture was stirred for 30 minutes 
at a temperature of 30˚C. Slowly temperature was raised 
to 115-120oC and maintained for 24 h. The reactant mass 
was cooled to 30-32°C and water (250 mL), 30% Sodium 
hydroxide (60 mL) and 30 % aqueous Sodium nitrite (60 
mL) were added and stirred for 30 minutes. Aqueous la-
yer was separated and washed with Xylene (50 mL). 25 
mL Ethyl Acetate added to aqueous layer and adjusted 
pH 3.0 – 4.0 using 6N hydrochloric acid. Reaction mass 
filtered and wet-cake washed with water (300 mL). To wet 
cake was added 1500 mL Isopropyl alcohol and refluxed 
till clear reaction mass. After charcoalization filtrate was 
distilled to half volume under reduced pressure. Resul-
tant mass was chilled at 0 - 5˚C, Maintain for 2 h at same 
temperature and Filtered. Wet cake dried under vacuum of 
about 10 mmHg. 
HPLC purity – 99.0%  ; Dry weight of Product: 70 g
Analysis Data: 
Melting Point:  180–182°C;
IR Data: (KBr, cm-1): NH 3447, CO 1733; NMR Data: 1H 
NMR : (DMSO d6): δppm 0.7–0.9 (t, 3H, CH3), 1.17–1.40 
(sextet, 2H, CH2), 1.40–1.60 (quintet, 2H, CH2) 1.60–2.00 
(m, 8H, cyclopentyl), 2.2–2.4 (t, 2H, CH2), 4.60–4.80 (s, 2H, 
Ar-CH2), 7.32–7.95 (m, 8H, biphenyl); 
13C NMR: 14.5, 22.4, 
26.3, 27.4, 28.3, 37.7, 43.1, 76.7, 124.3, 127.1, 128.7, 
130.1, 131.4, 131.9, 137.2, 139.2, 141.9, 155.9, 162.0, 
186.5; Mass: MS(EI) calculated for C25H28N6O (M
+ + 1) 
:428.53, observed value : 429.53; CHN Analysis calcula-
ted for C25H28N6O: 70.07, 6.59, 19.61. Found: 70.35, 6.61, 
19.61.
Heavy metal: Less than 10 PPM
CONCLUSIONS
The present invention provides an improved process for 
the preparation of Irbesartan which is succinct, direct and 
industrially feasible. It also provides a process which eli-
minates the use of chromatographic purification at inter-
mediate stages, which is not feasible for commercial scale 
production. Yield and purity of Irbesartan is significantly 
high. We have successfully avoided use of costly and en-
vironmentally hazardous solvent / chemical reagents. Fi-
nally Irbesartan produce from this process is free from tin 
content.
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